A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Madison |
| State: |
|
Wisconsin |
| Zip Code: |
|
53792 |
| Conditions: |
|
Diabetes - Diabetes Mellitus, Type 1 |
| Purpose: |
|
This trial is conducted in Europe and North America. The aim of this trial is to investigate
if liraglutide treatment can increase the proportion of insulin-independent subjects one
year after islet cell transplantation who required only one (single-donor) islet cell
transplant.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Type 1 diabetes mellitus for at least 5 years
- Candidate for islet cell transplantation based upon local accepted practice and
guidelines
- Reduced awareness of hypoglycaemia
Exclusion Criteria:
- Treatment with any anti-diabetic medication other than insulin including insulin pump
within 4 weeks of trial start
- Any previous organ transplantation
- A history of acute idiopathic or chronic pancreatitis
- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
medullary thyroid carcinoma (FMTC)
|
| NCT ID: |
|
NCT01206101 |
| Primary Contact: |
|
Study Director
Birgitte Claudius
Novo Nordisk
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Madison, Wisconsin 53792
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|